3D Medicines Inc. (HKG:1244)
Hong Kong · Delayed Price · Currency is HKD
3.800
+0.330 (9.51%)
At close: Mar 6, 2026
Revenue by Segment
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
Biopharmaceutical Research and Development | 445.65M | 634.95M | 567.39M | 60.26M |
Biopharmaceutical Research and Development Growth | -29.81% | 11.91% | 841.57% | - |
| 445.65M | 634.95M | 567.39M | 60.26M |
| -29.81% | 11.91% | 841.57% | - |
Revenue by Geography
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
| 445.65M | 634.95M | 567.39M | 60.26M |
| -29.81% | 11.91% | 841.57% | - |
| 445.65M | 634.95M | 567.39M | 60.26M |
| -29.81% | 11.91% | 841.57% | - |
Source: S&P Global Market Intelligence.
